In the context of adult pathology, research into biomarkers in cerebrospinal fluid (CSF) has already identified proteins that are commonly used for the early diagnosis of certain neurodegenerative diseases. However, the lack of data available in the literature on pediatric diseases has limited the use of biomarkers in routine practice in children. Importantly, our group has pioneered the establishment of CSF biomarkers in children (e.g., measurement of interferon alpha in CSF by ultra-sensitive digital ELISA), which will undoubtedly be used in routine clinical practice in the future. In light of these arguments, the establishment of a CSF biobank will have major clinical implications, given the rarity of the diseases treated and the number of patients followed.
Neurosurgical procedure (EVD, VP shunt, VSG shunt, tumor surgery, spinal surgery with dural opening, ELD);
Lumbar puncture (LP).
Patients who have (or whose legal guardians, where applicable, have) consented to the storage and reuse of residual biological samples collected during the course of care within the biological collection.
None
Patients with a neurological condition diagnosed by a physician requiring cerebrospinal fluid (CSF) collection as a part of their health care
Cohort
Retrospective
Not listed
Longitudinal evolution of protein markers in CSF from patients with central nervous system involvement
Longitudinal changes in inflammatory protein levels in the CSF of patients with post-hemorrhagic hydrocephalus
Proteomic characterization of several neuroinflammatory diseases
Identification of biomarkers of severity in children with traumatic brain injury
Comparison of CSF biomarkers with data generated in serum (when available)
Proteomic analysis by comparing LCS biomarker results with data generated in serum, in order to discover new biomarkers relevant to the pathology under study.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
